About
Hepatic de novo lipogenesis (DNL) is the synthesis of fatty acids in the liver from their metabolic precursor acetyl-CoA and is an important pathway reflecting metabolic health. Abnormal regulation of hepatic DNL has been observed in insulin resistance, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) (1,2), which makes it an appealing target for the treatment of metabolic diseases. Quantifying DNL using stable isotopes, therefore, is a valuable pharmacodynamic (PD) marker in early clinical trials. ProSciento scientists have extensive experience in the use of stable-isotope tracer methodologies, including the measurement of DNL in phase 1 and phase 2 clinical trials.
![Hepatic De Novo Lipogenesis Assessment thumbnail](https://prosciento.com/wp-content/uploads/2021/12/thumbnail-15.png)
Recommended Materials
![Hepatic De Novo Lipogenesis Assessment thumbnail](https://prosciento.com/wp-content/uploads/2022/01/obesity-poster-1.png)
Posters
NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
![Hepatic De Novo Lipogenesis Assessment thumbnail](https://prosciento.com/wp-content/uploads/2022/01/obesity-poster-1.png)
Posters
NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
![Hepatic De Novo Lipogenesis Assessment thumbnail](https://prosciento.com/wp-content/uploads/2022/04/adipose-tissue-measurement.jpg)
Articles
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
Related Solutions
![Isotope Tracer Methodologies for Metabolic Clinical Trials thumbnail](https://prosciento.com/wp-content/uploads/2023/08/specialized-methods-stable-isotope-tracers-.jpg)
Specialized Methods
![Steatotic Liver Disease thumbnail](https://prosciento.com/wp-content/uploads/2023/08/our-metabolic-focus-mash-thumbnail.jpg)